• Sonuç bulunamadı

G Serum gamma-glutamyltransferase activity andacute coronary syndromesEditorial / Editöryal Yorum

N/A
N/A
Protected

Academic year: 2021

Share "G Serum gamma-glutamyltransferase activity andacute coronary syndromesEditorial / Editöryal Yorum"

Copied!
2
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2013;41(4):282-283 doi: 10.5543/tkda.2013.73930

Serum gamma-glutamyltransferase activity and

acute coronary syndromes

Editorial / Editöryal Yorum

Serum gama-glutamiltransferaz aktivitesi ve akut koroner sendrom

Department of Cardiology, Güven Hospital, Ankara

Hüseyin Bozbaş, M.D.

G

amma-glutamyltransferase (GGT) is an antioxi-dant enzyme involved in the extracellular catabo-lism of glutathione. Many studies have been carried out regarding the importance of oxidative stress and its relation with GGT. A large body of evidence from these studies has shown that independent of hepatic disease and alcohol consumption, high serum GGT concentrations were associated with atherosclerotic vascular disease and related conditions (coronary ar-tery disease [CAD], stroke, diabetes mellitus, and metabolic syndrome).[1-3]

As GGT may have a role in the process of low den-sity lipoprotein (LDL) oxidation, it is thought that ele-vated levels of this enzyme may help in risk stratifica-tion of patients with atherosclerotic vascular disease. It was shown that GGT has prognostic significance. Independent of the traditional atherosclerotic risk fac-tors, GGT has been identified as a determinant of total and cardiovascular mortality.[4] Although not clearly

shown, the close relation between GGT and cardio-vascular events might be explained by the fact that GGT is a marker of oxidative stress and inflammation. Serum GGT has been demonstrated in atherosclerotic plaques from coronary arteries, which can have a role in the progression/course of vascular disease.[5]

In recent studies, the relation between GGT and acute coronary syndrome (ACS) was evaluated.[6-8]

Lazzeri et al.[7] from Italy

showed that GGT level was an independent predictor of early mortality in patients

with ST elevation myocardial infarction.Doğan and colleagues[8] evaluated serum GGT levels in patients

with non-ST elevation ACS.They found higher se-rum GGT concentrations in these patients compared to controls. They also analyzed ACS patients regard-ing coronary angiographic findregard-ings. Higher serum GGT levels were detected in patients with significant coronary stenosis (luminal narrowing of least 50% in any major coronary artery) compared to those with non-significant coronary lesions. Significantly, in 12 months of follow-up, GGT levels were identified as a determinant of major cardiac events.

In this journal issue, Duran and colleagues[9]

evaluated the relation between serum GGT and bur-den of coronary atherosclerosis in patients presenting with ACS (non-ST elevation myocardial infarction and unstable angina pectoris). It is known that the more severe/diffuse the coronary lesions, the worse the prognosis in patients with CAD. To define the se-verity of coronary lesions, they used both Gensini and Syntax scoring systems. They found that serum GGT concentration increases as coronary lesions become more severe in accordance with each of these

classifi-Correspondence: Dr. Hüseyin Bozbaş. Şimşek Sokak, Paris Caddesi, No: 58, Kavaklıdere 06540 Ankara, Turkey.

Tel: +90 312 - 457 26 06 e-mail: hbozbas@gmail.com

© 2013 Turkish Society of Cardiology

282

Abbreviations:

(2)

cations. That is, patients with high Syntax and Gensini scores (high atherosclerotic burden) had higher serum GGT levels compared to those with low scores (low atherosclerotic burden). This is an interesting study evaluating a relation between serum GGT and coro-nary lesion severity in ACS patients, and it adds to the existing literature showing that serum GGT has a prognostic role in ACS patients and is correlated with disease burden.

In conclusion, serum GGT, which is a widely avail-able and low-cost parameter, can assist in determining the risk in patients with various forms of cardiovascu-lar diseases, including ACS. Further studies with cardiovascu- larg-er numblarg-ers of patients will provide more informative data on this subject.

Conflict-of-interest issues regarding the authorship or article: None declared

REFERENCES 1. Bozbaş H, Yıldırır A, Karaçağlar E, Demir O, Ulus T, Eroğlu S, et al. Increased serum gamma-glutamyltransferase activity in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2011;39:122-8. [CrossRef] 2. Ulus T, Yıldırır A, Sade LE, Balta S, Ozin B, Sezgin A, et al. Serum gamma-glutamyltransferase activity: a new marker for coronary artery bypass graft disease. Turk Kardiyol Dern Ars 2011;39(3):205-13. [CrossRef] 3. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of

im- paired fasting glucose or type 2 diabetes in middle-aged Japa-nese men. J Intern Med 2003;254:287-95. [CrossRef]

4. Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. Ath-erosclerosis 2010;208:564-71. [CrossRef]

5. Franzini M, Corti A, Martinelli B, Del Corso A, Emdin M, Parenti GF, et al. Gamma-glutamyltransferase activity in hu-man atherosclerotic plaques--biochemical similarities with the circulating enzyme. Atherosclerosis 2009;202:119-27. 6. Ulus T, Yildirir A, Sade LE, Temiz A, Polat E, Bozbaş H, et

al. Serum gamma-glutamyl transferase activity: new high-risk criteria in acute coronary syndrome patients? Coron Artery Dis 2008;19:489-95. [CrossRef]

7. Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini GF. The prognostic role of gamma-glutamyltransfer- ase activity in non-diabetic ST-elevation myocardial infarc-tion. Intern Emerg Med 2011;6:213-9. [CrossRef] 8. Dogan A, Icli A, Aksoy F, Varol E, Erdogan D, Ozaydin M, et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis 2012;23:39-44. 9. Duran M, Uysal OK, Yılmaz Y, Günebakmaz Ö, Arınç H,

Topsakal R, et al. Serum gamma-glutamyltransferase and the burden of atherosclerosis in patients with acute coronary syn-drome. Turk Kardiyol Dern Ars 2013;41:275-81.

Serum gamma-glutamyltransferase activity and acute coronary syndromes 283

Key words: Acute coronary syndrome; coronary artery disease;

gamma-glutamyltransferase/blood.

Anahtar sözcükler: Akut koroner sendrom; koroner arter hastalığı;

Referanslar

Benzer Belgeler

It may be considered that lower serum prolidase levels in pa- tients with ischemic DCM, which were normally expected to be higher in patients with ischemic etiology in other

If serum nitric oxide (NO) level detection was done long after CA, the results of the study will be affected, since risk fac- tors for coronary artery disease (CAD) such as

If serum nitric oxide (NO) level detection was done long after CA, the results of the study will be affected, since risk fac- tors for coronary artery disease (CAD) such as

During the year 2014, all patients undergoing coronary angiography with at least one major coronary occlusion (100% stenosis), or a stenosis of ≥95% with thrombolysis in

Conclusion: Our study indicates that decreased levels of NO are present in patients with CAE compared to patients with normal coronary arter- ies, supporting the hypothesis

To confirm this hypothesis, eGFR equations using serum cystatin C alone and in combination with serum creatinine were compared with the equation using serum creatinine alone

They aimed to investigate YKL-40 and C-reactive protein (CRP) levels in patients with isolated CAE compared to patients with normal coronary arteries and coronary artery

(10) found that serum uric acid levels were higher in patients with aortic dilation compared to the control group, and considered this a marker of increased oxidative stress..